Abstract:Xuan Wang, 1, &ast Yi-Fan Wang, 2, &ast Shi-Jun Wang 1 1 Department of Gynecology, Xuanwu Hospital Capital Medical University, Beijing, 100053, People's Republic of China; 2 Department of Gynecology, Beijing Youan Hospital Capital Medical University, Beijing, 100069, People's Republic of China &astThese authors contributed equally to this work Correspondence: Shi-Jun Wang, Department of Gynecology, Xuanwu Hospital Capital Medical University, No. 45 of Changchun Street, Xicheng District, Beijing, 100053, People's Republic of China, Tel + 86 15001119089, Email Objective: In this study, we investigated the value of molecular typing combined with integrated positron emission tomography (PET)/magnetic resonance imaging (MRI) semi-quantitative indices in endometrial cancer risk stratification. Methods: A retrospective study was conducted on 86 patients who were pathologically diagnosed with endometrial cancer and underwent surgical treatment after curettage at the Department of Obstetrics and Gynecology, Xuanwu Hospital, Capital Medical University between January 2017 and March 2023. Prior to surgery, each patient underwent integrated PET/MRI examination. The postoperative samples were subjected to pathological diagnosis, immunohistochemistry, and POLE gene sequencing. The differences in clinicopathological features between the four molecular subtypes and the differences in integrated PET/MRI semi-quantitative indexes (SUV max, ADC min) between the four molecular subtypes were analyzed. The cutoff value of molecular typing combined with integrated PET/MRI semi-quantitative indices for endometrial cancer risk stratification was determined. Results: There were statistically significant differences in pathological types and tumor grades among the four molecular subtypes of endometrial cancer. The values of the four integrated PET/MRI semi-quantitative indices (SUV max and ADC min) of the molecular subtypes were statistically different. The SUV max was greater in the p53abn mutation group than in the POLE mutation group ( P < 0.05). The ADC minimum of the POLE mutation group and the MMR-d group was lower than the NSMP group ( P Conclusion: Molecular typing combined with integrated PET/MRI semi-quantitative indicators is useful to achieve risk stratification in patients diagnosed with endometrial cancer and guide individualized treatment. Keywords: endometrial cancer, integrated PET/MRI, individualized treatment, molecular typing Endometrial cancer (EC) is a malignant tumor originating from the endometrium, that is more prevalent in elderly women. The incidence of endometrial cancer in malignant tumors of the female genital tract can reach 20%–30%. With the evolution of the modern lifestyle and the extension of life expectancy, the global incidence of EC has been increasing annually and has become prevalent in younger women over the past two decades. 1 Patients diagnosed with endometrial cancer are typically treated with surgery. The scope of surgery is determined by a comprehensive preoperative evaluation. Diagnostic curettage is performed to determine the pathological diagnosis to obtain histological subtypes and grades, and iconography is used for preoperative staging. With the development of precision medicine, the standard pathomorphological classification is no longer adequate for clinical diagnosis and treatment. Along with the advancement of genomics research, molecular classification of endometrial cancer is being carried out to provide more tumor biological information. In 2013, the Cancer Genome Atlas Program (TCGA) conducted a large-scale, comprehensive, and integrated genomic analysis of 373 cases of endometrial cancer, which was divided into four molecular subtypes based on different clinicopathological and molecular characteristics, namely POLE exonuclease domain mutations (POLE) exonuclease domain mutations (POLE mut), microsatellite instability-high mutation (MSI-H), copy number abnormalities-low (CN-L), and copy number abnormalities-high (CN-H). Among these four molecular subtypes, the POLE mutant type had the best prognosis, followed by the CN-L type, MSI-H type, and CN-H type, which had the worst prognosis. 2 Nevertheless, the widespread clinical utilization of TCGA molecular typing diagnostic technology has been impeded by its high cost. In 2015, McConechy et al 3 sought to simplify the TCGA detection method. They accomplished this by employing immunohistochemical staining for mismatch repair (MMR) proteins and p53 protein, as well as sequencing the POLE gene. This simplified approach was extended beyond endometrial cancer to include non-endometrioid adenocarcinoma. As a result -Abstract Truncated-

The clinical utility of next generation sequencing in endometrial cancer: focusing on molecular subtyping and lynch syndrome

Identification of molecular subtypes for endometrial carcinoma using a 46-gene next-generation sequencing panel: a retrospective study on a consecutive cohort

A new strategy in molecular typing: the accuracy of an NGS panel for the molecular classification of endometrial cancers

Adoption of Universal Testing in Endometrial Cancers for Microsatellite Instability Using Next-Generation Sequencing

787P A NGS Panel for Molecular Classification of Endometrial Carcinoma

Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population

Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma

Application of NGS molecular classification in the diagnosis of endometrial carcinoma: A supplement to traditional pathological diagnosis

Approaches for Lynch syndrome screening and characteristics of subtypes with mismatch repair deficiency in patients with colorectal carcinoma

Utility of germline multi-gene panel testing in patients with endometrial cancer

Genetic spectrum of familial colorectal cancer based on Chinese clinical criteria of Lynch syndrome: study based on a multicenter population

Molecular classification grade 3 endometrial endometrioid carcinoma using a next-generation sequencing-based gene panel

[Comparative study of next generation sequencing and immunohistochemistry on molecular classification of endometrial carcinoma]

Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China

Screening and Identification of Lynch Syndrome: a Systematic Review of the Frequency of Lynch Syndrome-Associated Clinicopathologic and Molecular Characteristics in Lynch Syndrome Gynecologic Cancers

Prospective Clinical Prognostication of Endometrial Carcinomas Based on Next-Generation Sequencing and Immunohistochemistry-Real-World Implementation and Results at a Tertiary Care Center

Comparison of immediate germline sequencing and multi-step screening for Lynch syndrome detection in high-risk endometrial and colorectal cancer patients

Molecular Classification of Endometrial Cancer of Chinese Population.

Value of Molecular Typing Combined with Integrated Positron Emission Tomography/Magnetic Resonance Imaging in Risk Stratification of Endometrial Cancer

[Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma]

Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer